|Support type:||Scholarships in Brazil - Master|
|Effective date (Start):||March 01, 2010|
|Effective date (End):||January 31, 2012|
|Field of knowledge:||Health Sciences - Medicine - Medical Clinics|
|Principal Investigator:||Sara Teresinha Olalla Saad|
|Home Institution:||Centro de Hematologia e Hemoterapia (HEMOCENTRO). Universidade Estadual de Campinas (UNICAMP). Campinas , SP, Brazil|
|Associated research grant:||05/51681-1 - Functional investigation and characterization of the involvement of novel target genes and new therapeutics for myelodysplastic and leukemia lineages, AP.TEM|
The myelodysplastic syndrome (MDS) is caused by a complex group of setbacks in hematopoietic stem cells and is characterized by cytopenia in peripheral blood. With the progression of the disease patients are at risk of developing acute myeloid leukemia (AML). Most patients with MDS and acute leukemia (AL) are resistant to treatment and between 10 to 20% of patients with acute leukemia have acquired the disease due to previous chemotherapy. The enzymes of the family of genes CYP, GST, NQO1 and MDR-1 are directly related to biotransformation of chemotherapeutic agents. The resistance of patients to treatment may be related to polymorphic forms of these enzymes. The aim of this study is to investigate the influence of CYP2B6 G15631T, GSTM1, GSTT1, NQO1 C609T and MDR-1 C3435T polymorphisms in the response to treatment of AL and the progression of SMD. To identify DNA polymorphisms will be used from patients with a history of these diseases, extracted from peripheral blood samples. There will be a PCR reaction followed by enzymatic digestion and analysis in agarose gel allowing the identification of polymorphisms. The data will be analyzed and compared the response of patients to treatment. It is expected a more effective response in patients who do not have any of the polymorphisms studied.